Новые подходы к оценке сердечно-сосудистой токсичности у пациентов с гематологическими злокачественными опухолями (обзор литературы)

ОСЛОЖНЕНИЯ ПРОТИВООПУХОЛЕВОГО ЛЕЧЕНИЯ , , , ,

О.Е. Данилова, Г.Р. Гиматдинова, И.Л. Давыдкин, О.В. Терешина, В.Д. Сабанова, Г.И. Давыдкин

ФГБОУ ВО «Самарский государственный медицинский университет» Минздрава России, ул. Чапаевская, д. 89, Самара, Российская Федерация, 443099

Для переписки: Гелия Рифкатовна Гиматдинова, ул. Чапаевская, д. 89, Самара, Российская Федерация, 443099; тел.: +7(919)809-68-56; e-mail: gimatdinova1995@icloud.com

Для цитирования: Данилова О.Е., Гиматдинова Г.Р., Давыдкин И.Л. и др. Новые подходы к оценке сердечно-сосудистой токсичности у пациентов с гематологическими злокачественными опухолями (обзор литературы). Клиническая онкогематология. 2023;16(3):331–6.

DOI: 10.21320/2500-2139-2023-16-3-331-336

РЕФЕРАТ

Начиная с 2016 г. управление сердечно-сосудистыми осложнениями регламентируется рядом документов, которые основаны на рекомендациях Европейского общества кардиологов и регулярно обновляются. В настоящем обзоре литературы представлены алгоритмы диагностики и коррекции нежелательных явлений со стороны сердечно-сосудистой системы, возникающих на фоне или после проведения противоопухолевой лекарственной терапии у пациентов с гематологическими злокачественными опухолями. Цель настоящей публикации заключается в анализе данных литературы, посвященных оптимизации ведения пациентов, находящихся на противоопухолевом лечении, возможностям по улучшению качества их жизни, а также снижению летальности от сердечно-сосудистых осложнений лекарственной терапии.

Ключевые слова: кардиотоксичность, кардиоонкология, онкология, сердечно-сосудистые осложнения, химиотерапия.

Получено: 14 января 2023 г.

Принято в печать: 3 июня 2023 г.

Читать статью в PDF

Статистика Plumx русский

ЛИТЕРАТУРА

  1. Статистические данные по заболеваемости в Российской Федерации (электронный документ). Доступно по: https://rosstat.gov.ru/ Ссылка активна на 12.04.2023.
    [Statistical data on morbidity in the Russian Federation (Internet). Available from: https://rosstat.gov.ru/ Accessed 04.2023. (In Russ)]
  2. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660.
  3. Kalsbeek R, Mulder R, Skinner R. The Concept of Cancer Survivorship and Models for Long-Term Follow-Up. Front Horm Res. 2021;54:1–15. doi: 10.1159/000514693.
  4. Lancellotti P, Suter T, Lopez-Fernandez T, et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J. 2019;40(22):1756–63. doi: 10.1093/eurheartj/ehy453.
  5. Gilchrist S, Barac A, Ades P. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement from the American Heart Association. Circulation. 2019;139(21):e997–e1012. doi: 10.1161/CIR.0000000000000679.
  6. Visseren F, Mach F, Smulders Y, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. doi: 10.1093/eurheartj/ehab484.
  7. Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail. 2018;20(12):1721–31. doi: 10.1002/ejhf.1292.
  8. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502. doi: 10.1038/s41569-020-0348-1.
  9. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17(8):503–22. doi: 10.1038/s41569-020-0347-2.
  10. Armenian S, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893–911. doi: 10.1200/JCO.2016.70.5400.
  11. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. doi: 10.1016/j.annonc.2019.10.023.
  12. Lyon A, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–60. doi: 10.1002/ejhf.1920.
  13. McDonagh T, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. doi: 10.1093/eurheartj/ehab368.
  14. Caro-Codon J, Lopez-Fernandez T, Alvarez-Ortega C, et al. Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol. 2022;29(6):859–68. doi: 10.1093/eurjpc/zwaa034.
  15. Koene R, Prizment A, Blaes A, et al. Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation. 2016;133(11):1104–14. doi: 10.1161/CIRCULATIONAHA.115.020406.
  16. Zamorano J, Gottfridsson C, Asteggiano R, et al. The cancer patient and cardiology. Eur J Heart Fail. 2020;22(12):2290–309. doi: 10.1002/ejhf.1985.
  17. Lopez-Sendon J, Alvarez-Ortega C, Aunon O, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41(18):1720–9. doi: 10.1093/eurheartj/ehaa006.
  18. Holtermann A, Marott J, Gyntelberg F, et al. Self-reported cardiorespiratory fitness: prediction and classification of risk of cardiovascular disease mortality and longevity—a prospective investigation in the Copenhagen City Heart Study. J Am Heart Assoc. 2015;4(1):e001495. doi: 10.1161/JAHA.114.001495.
  19. Wickramasinghe C, Ayers C, Das S, et al. Prediction of 30-year risk for cardiovascular mortality by fitness and risk factor levels: the Cooper Center Longitudinal Study. Circ Cardiovasc Qual Outcomes. 2014;7(4):597–602. doi: 10.1161/CIRCOUTCOMES.113.000531.
  20. Pituskin E, Mackey J, Koshman S. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. J Clin Oncol. 2017;35(8):870–7. doi: 10.1200/JCO.2016.68.7830.
  21. Lyon A, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. doi: 10.1093/eurheartj/ehac244.
  22. NIH, National Cancer Institute, Department of Cancer Treatment and Diagnosis (Internet). Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed04.2023).
  23. Herrmann J, Yang E, Iliescu C, et al. Vascular Toxicities of Cancer Therapies: The Old and the New—An Evolving Avenue. Circulation. 2016;133(13):1272–89. doi: 10.1161/CIRCULATIONAHA.115.018347.
  24. Ferdinandy P, Baczko I, Bencsik P, et al. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J. 2019;40(22):1771–7. doi: 10.1093/eurheartj/ehy365.
  25. Lopez-Fernandez T, Garcia AM, Beltran AS, et al. Cardio-onco-hematology in clinical practice. Position paper and recommendations. Rev. Espanola Cardiol (Engl Ed). 2017;70(6):474–86. doi: 10.1016/j.rec.2016.12.041.
  26. Shah C, Moreb J. Cardiotoxicity due to targeted anticancer agents: a growing challenge. Ther Adv Cardiovasc Dis. 2019;13:1753944719843435. doi: 10.1177/1753944719843435.
  27. Lyman G, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–74. doi: 10.1182/bloodadvances.2020003442.
  28. Alexandre J, Salem J, Moslehi J, et al. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312–20. doi: 10.1093/ehjcvp/pvaa037.
  29. Liu J, Barac A, Thavendiranathan P, et al. Strain Imaging in Cardio-Oncology. JACC CardioOncol. 2020;2(5):677–89. doi: 10.1016/j.jaccao.2020.10.011.
  30. Eschenhagen T, Force T, Ewer M. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(1):1–10. doi: 10.1093/eurjhf/hfq213.
  31. Lapinskas T, Hireche-Chikaoui H, Zieschang V, et al. Effect of comprehensive initial training on the variability of left ventricular measures using fast-SENC cardiac magnetic resonance imaging. Sci Rep. 2019;9(1):12223. doi: 10.1038/s41598-019-48685-1.
  32. Yancy C, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–e161. doi: 10.1161/CIR.0000000000000509.
  33. Ghatalia P, Morgan C, Je Y, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015;94(2):228–37. doi: 10.1016/j.critrevonc.2014.12.008.
  34. Buza V, Rajagopalan B, Curtis AВ. Cancer Treatment–Induced Arrhythmias. Focus on Chemotherapy and Targeted Therapies. Circ Arrhythm Electrophysiol. 2017;10(8):e005443. doi:1161/CIRCEP.117.005443.
  35. Common Terminology Criteria for Adverse Events (CTCAE) v6.0. National Cancer Institute, 2022 (Internet). Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed04.2023).
  36. Mrotzek S, Lena A, Hadzibegovic S, et al. Assessment of coronary artery disease during hospitalization for cancer treatment. Clin Res Cardiol. 2021;110(2):200–10. doi: 10.1007/s00392-020-01719-5.
  37. Asteggiano R, Aboyans V, Lee G, et al. Cardiology care delivered to cancer patients. Eur Heart J. 2020;41(2):205–6. doi: 10.1093/eurheartj/ehz935.
  38. Aktaa S, Batra G, Wallentin L, et al. European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes. 2022;8(1):4–13. doi: 10.1093/ehjqcco/qcaa069.
  39. Когония Л.М., Русанов М.О., Шикина В.Е. Кардиотоксичность противоопухолевых препаратов и лучевой терапии у пациентов со злокачественными заболеваниями крови и сóлидными злокачественными новообразованиями. Онкогематология. 2022;17(3):127–36. doi: 10.17650/1818-8346-2022-17-3-127-136.
    [Kogoniya LM, Rusanov MO, Shikina VE. Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors. Oncohematology. 2022;17(3):127–36. doi: 10.17650/1818-8346-2022-17-3-127-136. (In Russ)]
  40. Nabhan C, Krett N, Gandhi V, et al. Gemcitabine in hematologic malignancies. Curr Opin Oncol. 2001;13(6):514–21. doi: 10.1097/00001622-200111000-00015.
  41. Hilmi M, Ederhy S, Waintraub X, et al. Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. Pharmaceuticals (Basel). 2020;13(10):325. doi: 10.3390/ph13100325.
  42. Hazam R, Taha A, Kimbugwe J, et al. Gemcitabine-Related Acute Coronary Syndrome. J Med Cases. 2020;11(1):30–3. doi: 10.14740/jmc3417.
  43. Salem J, Manouchehri A, Bretagne M, et al. Cardiovascular Toxicities Associated With Ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–78. doi: 10.1016/j.jacc.2019.07.056.
  44. Francisco A, Alves D, David C, et al. Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe? Cardiovasc Toxicol. 2018;18(5):431–5. doi: 10.1007/s12012-018-9453-3.
  45. Singh AP, Umbarkar P, Tousif S, Lal H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. Int J Cardiol. 2020;316:214–21. doi: 10.1016/j.ijcard.2020.05.077.
  46. Fradley M, Groarke J, Laubach J, et al. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Br J Haematol. 2018;180(2):271–5. doi: 10.1111/bjh.14970.
  47. Li W, Garcia D, Cornell F, et al. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. JAMA Oncol. 2017;3(7):980–8. doi: 10.1001/jamaoncol.2016.3350.
  48. Gavazzoni M, Lombardi CМ, Vizzardi E, et al. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. Eur J Pharmacol. 2018;838:85–90. doi: 10.1016/j.ejphar.2018.09.014.
  49. Johnson D, Balko J, Compton M, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749–55. doi: 10.1056/NEJMoa1609214.
  50. Hu J, Florido R, Lipson E, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–68. doi: 10.1093/cvr/cvz026.
  51. Rubio-Infante N, Ramirez-Flores YА, Castillo EС, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23(10):1739–47. doi: 10.1002/ejhf.2289.
  52. Nimwegen F, Schaapveld M, Cutter D, et al. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol. 2016;34(3):235–43. doi: 10.1200/JCO.2015.63.4444.